HRP20201013T1 - Liječenje autoimunih poremećaja protutijelima protiv cd154 - Google Patents
Liječenje autoimunih poremećaja protutijelima protiv cd154 Download PDFInfo
- Publication number
- HRP20201013T1 HRP20201013T1 HRP20201013TT HRP20201013T HRP20201013T1 HR P20201013 T1 HRP20201013 T1 HR P20201013T1 HR P20201013T T HRP20201013T T HR P20201013TT HR P20201013 T HRP20201013 T HR P20201013T HR P20201013 T1 HRP20201013 T1 HR P20201013T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- specifically binds
- autoimmune
- neurodegenerative
- inflammatory
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims 10
- 230000001363 autoimmune Effects 0.000 claims 9
- 208000027866 inflammatory disease Diseases 0.000 claims 9
- 230000002757 inflammatory effect Effects 0.000 claims 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims 9
- 230000000626 neurodegenerative effect Effects 0.000 claims 9
- 208000018360 neuromuscular disease Diseases 0.000 claims 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 2
- 108010028780 Complement C3 Proteins 0.000 claims 1
- 102000016918 Complement C3 Human genes 0.000 claims 1
- 108010028778 Complement C4 Proteins 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229920001427 mPEG Polymers 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
Claims (9)
1. Jednovalentni Fab’ fragment protutijela koje se specifično veže na CD154, namijenjen upotrebi u postupku liječenja autoimunog, upalnog, neurodegenerativnog ili neuromuskularnog poremećaja kod ljudskog subjekta, naznačen time što se postupak sastoji u:
a) primjeni početne doze punjenja od 20-60 mg/kg navedenog fragmenta protutijela koje se specifično veže na CD154 na ljudskom subjektu kojem je potrebno takvo liječenje; i
b) 2 tjedana nakon početne doze punjenja primjeni daljnje doze ili doza upola manjih od početne doze punjenja, uz učestalost od jednom u svaka dva tjedna navedenog fragmenta protutijela koje se specifično veže na CD154 na subjektu kojem je potrebno takvo liječenje,
gdje navedeni fragment protutijela ima slijed lakog lanca prikazan u SEQ ID NO:9 i sljedove teškog lanca prikazane u SEQ ID NO:10, i
gdje navedeni fragment protutijela ima
i) maleimidnu skupinu kovalentno vezanu na jednu tiolnu skupinu u modificiranom području zgloba, te lizinski ostatak kovalentno vezan na maleimidnu skupinu; i
ii) metoksipoli(etilenglikol)ni polimer molekulske težine od otprilike 20 kDa, vezan na svaku od aminskih skupina u lizinskom ostatku.
2. Jednovalentni Fab’ fragment protutijela koje se specifično veže na CD 154, namijenjen upotrebi u postupku liječenja autoimunog, upalnog, neurodegenerativnog ili neuromuskularnog poremećaja u skladu s patentnim zahtjevom 1, naznačen time što je početna doza punjenja 30 mg/kg, a daljnja doza je 15 mg/kg.
3. Jednovalentni Fab’ fragment protutijela koje se specifično veže na CD154, namijenjen upotrebi u postupku liječenja autoimunog, upalnog, neurodegenerativnog ili neuromuskularnog poremećaja u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se fragment protutijela koje se specifično veže na CD154 primijenjuje na pacijentu kojem je to potrebno u najmanju ruku u trajanju od 12 tjedana.
4. Jednovalentni Fab’ fragment protutijela koje se specifično veže na CD154, namijenjen upotrebi u postupku liječenja autoimunog, upalnog, neurodegenerativnog ili neuromuskularnog poremećaja kod ljudskog subjekta u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je bolest sistemni eritematozni lupus (SLE), lupozni nefritis, reumatoidni artritis, seronegativne spondiloartropatije, psorijaza, psorijatični artritis, skleroderma, Sjögrenov sindrom, multipla skleroza, dijabetes tip I, autoimuni uveitis i nefrotski sindrom ili vaskulitis.
5. Jednovalentni Fab’ fragment protutijela koje se specifično veže na CD154, namijenjen upotrebi u postupku liječenja autoimunog, upalnog, neurodegenerativnog ili neuromuskularnog poremećaja kod ljudskog subjekta u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni poremećaj sistemni eritematozni lupus (SLE), te što liječeni subjekt postiže poboljšanje u odnosu na polazne vrijednosti of one ili more of the indices selected from SLEDAI, BILAG i Global Physician assessment.
6. Jednovalentni Fab’ fragment protutijela koje se specifično veže na CD154, namijenjen upotrebi u postupku liječenja autoimunog, upalnog, neurodegenerativnog ili neuromuskularnog poremećaja kod ljudskog subjekta u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni poremećaj sistemni eritematozni lupus (SLE), te što liječeni subjekt postiže SLEDAI Responder Index 4 (SRI-4).
7. Jednovalentni Fab’ fragment protutijela koje se specifično veže na CD154, namijenjen upotrebi u postupku liječenja autoimunog, upalnog, neurodegenerativnog ili neuromuskularnog poremećaja kod ljudskog subjekta u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni poremećaj sistemni eritematozni lupus (SLE), te što liječeni subjekt postiže 50%-tno poboljšanje u odnosu na polazne vrijednosti indeksa SRI-50.
8. Jednovalentni Fab’ fragment protutijela koje se specifično veže na CD154, namijenjen upotrebi u postupku liječenja autoimunog, upalnog, neurodegenerativnog ili neuromuskularnog poremećaja kod ljudskog subjekta u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni poremećaj sistemni eritematozni lupus (SLE), te što liječeni subjekt postiže povećanje od 20%, 30%, 40%, 50%, 75% ili 90% u odnosu na polazne vrijednosti ili normaliziranje koncentracije komplementa C3 i C4, ili smanjenje od 20%, 30%, 40%, 50%, 75% ili 90% titra protutijela protiv dvolančane DNA u serumu.
9. Jednovalentni Fab’ fragment protutijela koje se specifično veže na CD154, namijenjen upotrebi u postupku liječenja autoimunog, upalnog, neurodegenerativnog ili neuromuskularnog poremećaja kod ljudskog subjekta u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni poremećaj sistemni eritematozni lupus (SLE), te što se subjekt vraća od seropozitivnog u seronegativnog na protutijela protiv dvolančane DNA.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1501613.2A GB201501613D0 (en) | 2015-01-30 | 2015-01-30 | Treatment of autoimmune disorders with CD154 antibodies |
| EP15719675.9A EP3250600B1 (en) | 2015-01-30 | 2015-04-27 | Treatment of autoimmune disorders with cd154 antibodies |
| PCT/EP2015/059095 WO2016119909A1 (en) | 2015-01-30 | 2015-04-27 | Treatment of autoimmune disorders with cd154 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201013T1 true HRP20201013T1 (hr) | 2020-10-16 |
Family
ID=52705552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201013TT HRP20201013T1 (hr) | 2015-01-30 | 2020-06-26 | Liječenje autoimunih poremećaja protutijelima protiv cd154 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20180022812A1 (hr) |
| EP (2) | EP3250600B1 (hr) |
| KR (1) | KR102543877B1 (hr) |
| CN (1) | CN107206075A (hr) |
| AU (2) | AU2015379642B2 (hr) |
| CA (1) | CA2975336C (hr) |
| CY (1) | CY1123116T1 (hr) |
| DK (1) | DK3250600T3 (hr) |
| ES (1) | ES2802982T3 (hr) |
| GB (1) | GB201501613D0 (hr) |
| HR (1) | HRP20201013T1 (hr) |
| HU (1) | HUE050024T2 (hr) |
| LT (1) | LT3250600T (hr) |
| NZ (1) | NZ733454A (hr) |
| PL (1) | PL3250600T3 (hr) |
| PT (1) | PT3250600T (hr) |
| RS (1) | RS60575B1 (hr) |
| RU (1) | RU2695443C2 (hr) |
| SI (1) | SI3250600T1 (hr) |
| WO (1) | WO2016119909A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3556774T3 (fi) | 2011-03-11 | 2024-03-15 | Beth Israel Deaconess Medical Ct Inc | Anti-cd40-vasta-aineita ja niiden käyttötapoja |
| SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
| US11099185B2 (en) * | 2016-02-29 | 2021-08-24 | Maintect Gmbh | Predictive markers useful in the treatment of wet age-related macular degeneration |
| WO2020068723A1 (en) * | 2018-09-24 | 2020-04-02 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| CN113447659B (zh) * | 2021-07-01 | 2022-05-17 | 浙江大学 | 一种检测抗蛋白酶体亚基α1-IgG抗体的试剂盒 |
| WO2023099607A1 (en) * | 2021-12-01 | 2023-06-08 | UCB Biopharma SRL | Formulations comprising fab-peg |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| CN101679521B (zh) | 2007-03-22 | 2014-03-12 | 拜奥根Idec马萨诸塞公司 | 特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途 |
| JP2012511014A (ja) * | 2008-12-05 | 2012-05-17 | エイエルエス・セラピー・デベロップメント・インスティテュート | 神経変成疾患を治療する方法 |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2012149228A1 (en) | 2011-04-26 | 2012-11-01 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
-
2015
- 2015-01-30 GB GBGB1501613.2A patent/GB201501613D0/en not_active Ceased
- 2015-04-27 DK DK15719675.9T patent/DK3250600T3/da active
- 2015-04-27 SI SI201531299T patent/SI3250600T1/sl unknown
- 2015-04-27 KR KR1020177024036A patent/KR102543877B1/ko active IP Right Grant
- 2015-04-27 WO PCT/EP2015/059095 patent/WO2016119909A1/en active Application Filing
- 2015-04-27 PT PT157196759T patent/PT3250600T/pt unknown
- 2015-04-27 CN CN201580074799.1A patent/CN107206075A/zh active Pending
- 2015-04-27 CA CA2975336A patent/CA2975336C/en active Active
- 2015-04-27 HU HUE15719675A patent/HUE050024T2/hu unknown
- 2015-04-27 EP EP15719675.9A patent/EP3250600B1/en active Active
- 2015-04-27 AU AU2015379642A patent/AU2015379642B2/en active Active
- 2015-04-27 RU RU2017130464A patent/RU2695443C2/ru active
- 2015-04-27 PL PL15719675T patent/PL3250600T3/pl unknown
- 2015-04-27 RS RS20200831A patent/RS60575B1/sr unknown
- 2015-04-27 EP EP20172402.8A patent/EP3744735A1/en active Pending
- 2015-04-27 US US15/547,223 patent/US20180022812A1/en not_active Abandoned
- 2015-04-27 NZ NZ733454A patent/NZ733454A/en unknown
- 2015-04-27 ES ES15719675T patent/ES2802982T3/es active Active
- 2015-04-27 LT LTEP15719675.9T patent/LT3250600T/lt unknown
-
2020
- 2020-06-26 HR HRP20201013TT patent/HRP20201013T1/hr unknown
- 2020-07-10 CY CY20201100635T patent/CY1123116T1/el unknown
-
2021
- 2021-06-29 US US17/361,393 patent/US11884737B2/en active Active
-
2022
- 2022-01-19 AU AU2022200347A patent/AU2022200347A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016119909A1 (en) | 2016-08-04 |
| KR102543877B1 (ko) | 2023-06-14 |
| GB201501613D0 (en) | 2015-03-18 |
| KR20170106476A (ko) | 2017-09-20 |
| US20210324095A1 (en) | 2021-10-21 |
| AU2015379642A1 (en) | 2017-07-27 |
| US11884737B2 (en) | 2024-01-30 |
| RU2695443C2 (ru) | 2019-07-23 |
| RU2017130464A3 (hr) | 2019-02-28 |
| CA2975336C (en) | 2022-10-18 |
| EP3250600A1 (en) | 2017-12-06 |
| CN107206075A (zh) | 2017-09-26 |
| CY1123116T1 (el) | 2021-10-29 |
| US20180022812A1 (en) | 2018-01-25 |
| PL3250600T3 (pl) | 2020-09-21 |
| SI3250600T1 (sl) | 2020-09-30 |
| AU2022200347A1 (en) | 2022-02-17 |
| RU2017130464A (ru) | 2019-02-28 |
| PT3250600T (pt) | 2020-06-17 |
| CA2975336A1 (en) | 2016-08-04 |
| EP3744735A1 (en) | 2020-12-02 |
| NZ733454A (en) | 2023-12-22 |
| RS60575B1 (sr) | 2020-08-31 |
| AU2015379642B2 (en) | 2021-11-04 |
| HUE050024T2 (hu) | 2020-11-30 |
| ES2802982T3 (es) | 2021-01-22 |
| DK3250600T3 (da) | 2020-06-08 |
| LT3250600T (lt) | 2020-07-27 |
| EP3250600B1 (en) | 2020-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201013T1 (hr) | Liječenje autoimunih poremećaja protutijelima protiv cd154 | |
| Cessak et al. | TNF inhibitors–Mechanisms of action, approved and off-label indications | |
| HRP20200174T1 (hr) | Antitijela antigena 2 anti-krvne dendritične stanice i njihova uporaba | |
| JP2017505622A5 (hr) | ||
| JP2017079785A5 (hr) | ||
| Crowley et al. | Enhancement of motor function recovery after spinal cord injury in mice by delivery of brain-derived neurotrophic factor mRNA | |
| HRP20191334T1 (hr) | Anti-fcrn antitijela | |
| RU2425841C2 (ru) | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 | |
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| RU2018111508A (ru) | Анти-LAG-3 антитела | |
| JP2020500542A5 (hr) | ||
| JP2020501550A5 (hr) | ||
| JP2018121657A5 (hr) | ||
| JP2014509510A5 (hr) | ||
| JP2011522832A5 (hr) | ||
| JP2014076062A5 (hr) | ||
| JP2012520308A5 (hr) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| Roberts et al. | Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis | |
| JP2013539468A5 (hr) | ||
| JP2015514110A5 (hr) | ||
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| ES2769123T3 (es) | Anticuerpos de quimiocinas PAN ELR+ CXC | |
| JP2013537418A5 (hr) | ||
| JP2015502340A5 (hr) |